A clinical trial investigates synergistic effects of osimertinib and capivasertib in NSCLC patients with resistance mutations, suggesting new treatment options.
Osimertinib (Osi) has become the standard of care for patients(pts) with EGFRm advanced NSCLC. However, drug resistance is inevitable. PIK3CA/AKT1/PTEN alterations, occurring in 10% to 16% pts after Osi, have been identified as a potential resistance mechanism to Osi. Preclinical data showed the potential anti-tumor effects of Osi combined with capivasertib (Capi), an orally pan-AKT inhibitor, in both vitro and vivo models of osimertinib-resistant tumors with PIK3CAm and PTEN alterations. Building on these findings, a clinical study was conducted to explore the synergistic effects of Osi with Capi in NSCLC pts who progress under Osi treatment due to PIK3CA/AKT/PTEN alterations.
No takes yet. Share an insight, caveat, or question.
Xu et al. (2026) studied this question.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: